RJA
PPH icon

Raymond James & Associates’s VanEck Pharmaceutical ETF PPH Stock Holding History

Raymond James & Associates’s Portfolio PPH Stock Details PPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$1.13M Sell
11,871
-324
-3% -$30.8K ﹤0.01% 2616
2024
Q2 		$1.12M Buy
12,195
+6,075
+99% +$542K ﹤0.01% 2554
2024
Q1 		$555K Buy
6,120
+1,155
+23% +$101K ﹤0.01% 3000
2023
Q4 		$404K Buy
4,965
+78
+2% +$6.12K ﹤0.01% 3085
2023
Q3 		$390K Buy
4,887
+800
+20% +$64.5K ﹤0.01% 3039
2023
Q2 		$322K Sell
4,087
-2,619
-39% -$205K ﹤0.01% 3214
2023
Q1 		$521K Sell
6,706
-23,307
-78% -$1.8M ﹤0.01% 2899
2022
Q4 		$2.33M Buy
30,013
+16,613
+124% +$1.23M ﹤0.01% 1895
2022
Q3 		$901K Buy
13,400
+40
+0.3% +$2.95K ﹤0.01% 2468
2022
Q2 		$1.03M Buy
13,360
+1,929
+17% +$151K ﹤0.01% 2425
2022
Q1 		$912K Buy
11,431
+1,144
+11% +$87.5K ﹤0.01% 2667
2021
Q4 		$792K Buy
+10,287
New +$765K ﹤0.01% 2779
2021
Q3 		– Sell
-3,609
Closed -$264K – 4224
2021
Q2 		$264K Sell
3,609
-12
-0.3% -$856 ﹤0.01% 3522
2021
Q1 		$250K Sell
3,621
-66
-2% -$4.55K ﹤0.01% 3481
2020
Q4 		$245K Sell
3,687
-600
-14% -$38.4K ﹤0.01% 3254
2020
Q3 		$267K Hold
4,287
– – ﹤0.01% 3026
2020
Q2 		$267K Buy
4,287
+78
+2% +$4.72K ﹤0.01% 2986
2020
Q1 		$229K Buy
4,209
+600
+17% +$36.9K ﹤0.01% 2944
2019
Q4 		$232K Buy
+3,609
New +$217K ﹤0.01% 3253
2019
Q2 		– Sell
-5,100
Closed -$310K – 3730
2019
Q1 		$310K Hold
5,100
– – ﹤0.01% 2963
2018
Q4 		$279K Sell
5,100
-84,114
-94% -$5.09M ﹤0.01% 2913
2018
Q3 		$5.74M Sell
89,214
-2,292
-3% -$143K 0.01% 1132
2018
Q2 		$5.4M Sell
91,506
-769
-0.8% -$44.6K 0.01% 1150
2018
Q1 		$5.24M Buy
92,275
+673
+0.7% +$40.2K 0.01% 1134
2017
Q4 		$5.43M Buy
91,602
+3,087
+3% +$177K 0.01% 1074
2017
Q3 		$5.11M Sell
88,515
-9,011
-9% -$512K 0.01% 1069
2017
Q2 		$5.76M Buy
97,526
+362
+0.4% +$20.5K 0.01% 974
2017
Q1 		$5.36M Buy
97,164
+2,055
+2% +$111K 0.01% 991
2016
Q4 		$4.99M Buy
95,109
+2,563
+3% +$137K 0.01% 990
2016
Q3 		$5.32M Buy
92,546
+4,043
+5% +$243K 0.01% 920
2016
Q2 		$5.19M Buy
88,503
+11,806
+15% +$688K 0.02% 836
2016
Q1 		$4.41M Buy
76,697
+66
+0.1% +$3.9K 0.01% 880
2015
Q4 		$5M Buy
76,631
+241
+0.3% +$15.6K 0.02% 809
2015
Q3 		$4.81M Sell
76,390
-2,247
-3% -$158K 0.02% 767
2015
Q2 		$5.56M Sell
78,637
-75
-0.1% -$5.4K 0.02% 758
2015
Q1 		$5.53M Sell
78,712
-2,665
-3% -$181K 0.02% 697
2014
Q4 		$5.23M Sell
81,377
-943
-1% -$60.1K 0.03% 664
2014
Q3 		$5.23M Sell
82,320
-16,500
-17% -$1.02M 0.03% 607
2014
Q2 		$6.13M Buy
98,820
+18,467
+23% +$1.1M 0.04% 542
2014
Q1 		$4.69M Buy
+80,353
New +$4.54M 0.03% 602

Other funds holding PPH

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
AT
Avalon Trust Santa Fe, New Mexico $1.45B AUM 35.31% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
MIM
Miller Investment Management West Conshohocken, Pennsylvania $1.01B AUM 13.96% 1-Year Est. Return
Northwestern Mutual Wealth Management
Northwestern Mutual Wealth Management Milwaukee, Wisconsin $162B AUM 16.35% 1-Year Est. Return
PCIA
Prime Capital Investment Advisors Overland Park, Kansas $8.65B AUM 19.52% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
FPGK
Financial Partners Group (Kansas) Overland Park, Kansas $985M AUM 29.69% 1-Year Est. Return

Raymond James & Associates's PPH Position: Q3 2024 in Review

Raymond James & Associates reduced its VanEck Pharmaceutical ETF (PPH) stake by 2.7% in Q3 2024, selling an estimated $30.8K and leaving 11,871 shares worth $1.13M. The position accounts for ﹤0.01% of the portfolio, ranked #2616.

Raymond James & Associates first reported a position in PPH in Q1 2014 and has held it in 40 quarters since. The position peaked at $6.13M in Q2 2014. 142 funds tracked by Wall St. Rank hold PPH as of Q3 2024.

  • Raymond James & Associates held 11,871 shares of VanEck Pharmaceutical ETF worth $1.13M as of Q3 2024.
  • Raymond James & Associates sold 324 VanEck Pharmaceutical ETF shares in Q3 2024, an estimated $30.8K.
  • VanEck Pharmaceutical ETF made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #2616 holding.
  • Raymond James & Associates first reported a position in VanEck Pharmaceutical ETF in Q1 2014 and has held it in 40 quarters since.
  • Raymond James & Associates's VanEck Pharmaceutical ETF position peaked at $6.13M in Q2 2014.
  • 142 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.